Business Context and Reporting Period
This Form 8-K was filed by Leap Therapeutics, Inc. (not Cypherpunk Technologies Inc.) on September 7, 2018. The registrant is a Delaware corporation and an emerging growth company headquartered in Cambridge, MA. The report details the entry into a material definitive agreement regarding a new equity distribution program.
Key Financial Metrics and Capital Structure
This filing does not report operational financial metrics such as revenue, profit, cash flow, or margins. The primary financial data relates to a capital raise mechanism:
- Maximum Proceeds: Up to $30.0 million in aggregate gross proceeds from the sale of common stock.
- Commission: 3.0% of aggregate gross proceeds payable to the agent.
- Stock Par Value: $0.001 per share.
- Debt and Liquidity: The filing text does not provide specific values for current debt levels or liquidity positions.
Material Changes and Agreements
On September 7, 2018, the Company entered into a Distribution Agreement with Raymond James & Associates, Inc. as the sales agent. Key terms include:
- Offering Type: "At-the-market" equity offerings under Rule 415, potentially including sales directly on or through the Nasdaq Global Market.
- Principal Sales: The Company may also sell shares to Raymond James as a principal at an agreed-upon price.
- Termination: The agreement terminates upon the sale of all shares or earlier termination by either party.
- Legal Basis: Sales are made pursuant to a shelf registration statement on Form S-3 (File No. 333-223419) declared effective on March 16, 2018.
Guidance, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond standard securities law disclaimers. The document notes that the report does not constitute an offer to sell securities in any state where such an offer would be unlawful prior to registration. The agreement includes customary indemnification and contribution rights for the agent.
Investor Verification Checklist
- Verify the discrepancy between the requested company name (Cypherpunk Technologies Inc.) and the actual registrant (Leap Therapeutics, Inc.).
- Confirm the status of the Form S-3 shelf registration (File No. 333-223419) and any subsequent sales activity under this agreement.
- Review the full text of the Distribution Agreement (Exhibit 1.1) for specific conditions to placement and termination rights.
- Check subsequent filings for actual proceeds raised and the number of shares sold under this $30.0 million program.